Nestlé Health Science Licenses Rights for LT-02 as Ulcerative Colitis Therapy

Nestlé Health Science Licenses Rights for LT-02 as Ulcerative Colitis Therapy
Nestlé Health Science recently announced that it has entered into a license partnership with Lipid Therapeutics, a biopharmaceutical company focused on the development and commercialization of phospholipids, for global exclusive rights (except in Australia and Europe) over Lipid Therapeutics’ LT-02 agent (phosphatidylcholine), a novel treatment able to improve the mucosal barrier function in patients with mild-to-moderate ulcerative colitis. Under the terms of the agreement, Nestlé will conduct the development and commercialization of LT-02 upon approval by authorities in the licensed geographic regions. In 2016, Nestlé expects to begin Phase III clinical studies in the United States. The financial details of the partnership are, however, undisclosed. The European development partner of Lipid Therapeutics, Dr. Falk Pharma GmbH, a pharmaceutical company dedicated to gastroenterology, revealed the initiation of phase III clinical studies for LT-02 in Europe last October. Under the terms of the development strategy, the three companies will collaborate to acquire clinical evidence supporting LT-02’s health effects as an ulcerative colitis treatment in order to obtain the drug's approval. Ulcerative colitis is an inflammatory disease of the colon and the prevalent opinion believes that an inflammation of the upper section of the colon’s mucosal wall is the cause for the disease. Accordingly, current treatment strategies like aminosalycilates (5-ASAs), steroids, immuno-suppressants and biologicals target the inflammatory cascade
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *